Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1968 3
1970 3
1971 2
1972 1
1973 7
1975 2
1976 3
1977 12
1978 11
1979 5
1980 7
1981 8
1982 4
1983 9
1984 3
1985 10
1986 12
1987 12
1988 8
1989 12
1990 15
1991 10
1992 18
1993 26
1994 21
1995 18
1996 29
1997 25
1998 23
1999 33
2000 33
2001 27
2002 50
2003 57
2004 51
2005 39
2006 51
2007 49
2008 24
2009 30
2010 29
2011 21
2012 21
2013 19
2014 20
2015 33
2016 20
2017 22
2018 29
2019 26
2020 34
2021 44
2022 24
Text availability
Article attribute
Article type
Publication date

Search Results

1,040 results
Results by year
Filters applied: . Clear all
Page 1
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; Japan Clinical Oncology Group Study JCOG9801. Tsukasaki K, et al. Among authors: ueda r. J Clin Oncol. 2007 Dec 1;25(34):5458-64. doi: 10.1200/JCO.2007.11.9958. Epub 2007 Oct 29. J Clin Oncol. 2007. PMID: 17968021 Clinical Trial.
Current status of immunotherapy.
Suzuki S, Ishida T, Yoshikawa K, Ueda R. Suzuki S, et al. Among authors: ueda r. Jpn J Clin Oncol. 2016 Mar;46(3):191-203. doi: 10.1093/jjco/hyv201. Epub 2016 Jan 26. Jpn J Clin Oncol. 2016. PMID: 26819277 Review.
Immunotherapeutic approaches for glioma.
Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M. Okada H, et al. Among authors: ueda r. Crit Rev Immunol. 2009;29(1):1-42. doi: 10.1615/critrevimmunol.v29.i1.10. Crit Rev Immunol. 2009. PMID: 19348609 Free PMC article. Review.
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Sakamoto Y, Ishida T, Masaki A, Murase T, Takeshita M, Muto R, Iwasaki H, Ito A, Kusumoto S, Nakano N, Tokunaga M, Yonekura K, Tashiro Y, Iida S, Utsunomiya A, Ueda R, Inagaki H. Sakamoto Y, et al. Among authors: ueda r. Br J Haematol. 2021 Nov;195(4):571-584. doi: 10.1111/bjh.17749. Epub 2021 Aug 17. Br J Haematol. 2021. PMID: 34405395 Free PMC article.
Immunopathogenesis of lymphoma: focus on CCR4.
Ishida T, Ueda R. Ishida T, et al. Among authors: ueda r. Cancer Sci. 2011 Jan;102(1):44-50. doi: 10.1111/j.1349-7006.2010.01767.x. Epub 2010 Nov 2. Cancer Sci. 2011. PMID: 21044233 Free article. Review.
[Thyroid gland primary leiomyosarcoma].
Bertelli AA, Massarollo LC, Volpi EM, Ueda RY, Barreto E. Bertelli AA, et al. Among authors: ueda ry. Arq Bras Endocrinol Metabol. 2010 Mar;54(3):326-30. doi: 10.1590/s0004-27302010000300012. Arq Bras Endocrinol Metabol. 2010. PMID: 20520964 Review. Portuguese.
CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia.
Karnan S, Hanamura I, Ota A, Takasugi S, Nakamura A, Takahashi M, Uchino K, Murakami S, Wahiduzzaman M, Quang Vu L, Rahman ML, Hasan MN, Hyodo T, Konishi H, Tsuzuki S, Yoshikawa K, Suzuki S, Ueda R, Ejiri M, Hosokawa Y, Takami A. Karnan S, et al. Among authors: ueda r. Cell Death Discov. 2021 May 25;7(1):121. doi: 10.1038/s41420-021-00446-8. Cell Death Discov. 2021. PMID: 34035227 Free PMC article.
1,040 results